Literature DB >> 25582330

Donepezil-ferulic acid hybrids as anti-Alzheimer drugs.

Mohamed Benchekroun1, Lhassane Ismaili, Marc Pudlo, Vincent Luzet, Tijani Gharbi, Bernard Refouvelet, José Marco-Contelles.   

Abstract

BACKGROUND: Due to the complex nature of Alzheimer's disease, there is a renewed and growing search for multitarget drugs.
RESULTS: Donepezil-ferulic acid hybrids (DFAHs) were prepared by the one-pot Ugi-4CR in low-to-moderate yields. DFAHs are potent antioxidant agents, showing oxygen radical absorbance capacity values in the range 4.80-8.71 trolox equivalents, quite higher compared with those recorded for ferulic acid and melatonin. From the ChEs inhibition studies, we conclude that DFAH 8, bearing an ethylene linker, and DFAH 12, bearing a propylene linker, both substituted with a melatonin motif, are the most potent inhibitors, in the nanomolar range.
CONCLUSION: We have identified DFAH 8 as a very potent antioxidant, and totally selective equineButyrylCholinEsterase (eqBuChE) inhibitor.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25582330     DOI: 10.4155/fmc.14.148

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  9 in total

Review 1.  The recent development of donepezil structure-based hybrids as potential multifunctional anti-Alzheimer's agents: highlights from 2010 to 2020.

Authors:  Rzgar Tawfeeq Kareem; Fahimeh Abedinifar; Evan Abdolkareem Mahmood; Abdol Ghaffar Ebadi; Fatemeh Rajabi; Esmail Vessally
Journal:  RSC Adv       Date:  2021-09-16       Impact factor: 4.036

2.  Triazolopyridopyrimidine: A New Scaffold for Dual-Target Small Molecules for Alzheimer's Disease Therapy.

Authors:  Lazhar Zribi; Irene Pachòn-Angona; Òscar M Bautista-Aguilera; Daniel Diez-Iriepa; José Marco-Contelles; Lhassane Ismaili; Isabel Iriepa; Fakher Chabchoub
Journal:  Molecules       Date:  2020-07-13       Impact factor: 4.411

Review 3.  Profiling donepezil template into multipotent hybrids with antioxidant properties.

Authors:  Eva Mezeiova; Katarina Spilovska; Eugenie Nepovimova; Lukas Gorecki; Ondrej Soukup; Rafael Dolezal; David Malinak; Jana Janockova; Daniel Jun; Kamil Kuca; Jan Korabecny
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

4.  Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer's disease therapy.

Authors:  Irene Pachón-Angona; Bernard Refouvelet; Rudolf Andrýs; Helène Martin; Vincent Luzet; Isabel Iriepa; Ignacio Moraleda; Daniel Diez-Iriepa; María-Jesús Oset-Gasque; José Marco-Contelles; Kamil Musilek; Lhassane Ismaili
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

5.  Synthesis and biological assessment of KojoTacrines as new agents for Alzheimer's disease therapy.

Authors:  Youssef Dgachi; Hélène Martin; Rim Malek; Daniel Jun; Jana Janockova; Vendula Sepsova; Ondrej Soukup; Isabel Iriepa; Ignacio Moraleda; Emna Maalej; M Carmo Carreiras; Bernard Refouvelet; Fakher Chabchoub; José Marco-Contelles; Lhassane Ismaili
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

6.  Design, Synthesis and Biological Evaluation of New Antioxidant and Neuroprotective Multitarget Directed Ligands Able to Block Calcium Channels.

Authors:  Irene Pachòn Angona; Solene Daniel; Helene Martin; Alexandre Bonet; Artur Wnorowski; Maciej Maj; Krzysztof Jóźwiak; Tiago Barros Silva; Bernard Refouvelet; Fernanda Borges; José Marco-Contelles; Lhassane Ismaili
Journal:  Molecules       Date:  2020-03-14       Impact factor: 4.411

7.  Synthesis of Hantzsch Adducts as Cholinesterases and Calcium Flux inhibitors, Antioxidants and Neuroprotectives.

Authors:  Irene Pachón Angona; Helene Martin; Solene Daniel; Ignacio Moraleda; Alexandre Bonet; Artur Wnorowski; Maciej Maj; Krzysztof Jozwiak; Isabel Iriepa; Bernard Refouvelet; José Marco-Contelles; Lhassane Ismaili
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

8.  Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors.

Authors:  Maja Przybyłowska; Krystyna Dzierzbicka; Szymon Kowalski; Klaudia Chmielewska; Iwona Inkielewicz-Stepniak
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 9.  From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer's Disease.

Authors:  Jazmín Alarcón-Espósito; Michael Mallea; Julio Rodríguez-Lavado
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.